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Recent studies indicate that immune development in humans and other species may be altered
after perinatal exposure to immunotoxic environmental contaminants. However, limited informa-
tion is available regarding appropriate tests that may adequately detect developmental immuno-
toxic compounds. Experiments in which pregnant laboratory rodents were exposed to a variety of
immunotoxic environmental agents indicate that fetal thymus and liver immune cells may be
quantitatively and qualitatively altered by immunotoxicant exposure and, thus, may serve as sen-
sitive markers of developmental immunotoxicant exposure. In particular, depression of fetal
thymic cell counts appears to be a common event following gestational exposure to immunotoxi-
cants that produce this response in adult animals. Total hematopoietic cell counts in fetal liver,
however, may be a poor indicator of immunotoxicant exposure. Altered marker expression in
both fetal thymus and liver appears to be a highly sensitive indicator of gestational immunotoxi-
cant exposure. Together, these reports suggest that immune tests with high predictability for
immunosuppression in adults may also be appropriate for the detection of developmental
immunotoxic agents. - Environ Health Perspect 104(Suppl 4):809-813 (1996)
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Background
Limited information is available on the
postnatal immune alterations that may
result from developmental (i.e., gestational)
exposure of humans and other species to
environmental immunotoxicants. However,
studies in laboratory rodents suggest that
perinatal treatment of animals with a vari-
ety of immunotoxic compounds may have
more dramatic and persistent effects on
subsequent immune function than does
exposure during adult life [see review by
Holladay and Luster (1)]. For example,
studies show that prenatal exposure of
mice to the organochlorine insecticide
chlordane results in significant depression
of cell-mediated immune responses in off-
spring that persist for at least 100 days after
birth (2,3). Alterations in the formation of
bone marrow colonies in these mice have
been observed to persist up to 200 days of
age (4). This latter effect in particular has
not been observed in adult mice after simi-
lar dosing with chlordane. Similar to chlor-
dane, the offspring ofpregnant mice treat-
ed with the polycyclic aromatic hydrocar-
bon (PAH), benzo[a]pyrene (B[a]P),
showed long-term (e.g., still present at 18
months of age) depression of antibody,
graft-versus-host, and mixed lymphocyte
responses (5). Similar changes in mice after
This paper is part of the Wingspread Work Session on Chemically-induced Alterations in the Developing
Immune System: The Wildlife/Human Connection held 10-12 February 1995 in Racine, Wisconsin. Manuscript
received 3 October 1995; manuscript accepted 15 December 1995.
Address correspondence to Dr. Steven D Holladay, Department of Biomedical Sciences, Virginia-Maryland
Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, Va 24061-0442. Telephone: (540) 231-3372.
Fax: (540) 231-7367. E-mail: holladay@vt.edu
Abbreviations: B[a]P, benzo[alpyrene; DDT, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane; DES, diethyl-
stilbesterol; DMBA, 7,12-dimethylbenz[alanthracene; DN, double negative; DP, double positive; EGME, ethyl-
ene glycol monomethyl ether; PAH, polycyclic aromatic hydrocarbon; PHAH, polycyclic halogenated hydrocar-
bons; SP, single positive; TCDD, tetrachlorodibenzo-p-dioxin; gd, gestational day; TdT, terminal deoxynu-
cleotidyltransferase.
gestational exposure to additional immuno-
toxic compounds have been associated with
reduced ability ofthe animals to withstand
immunologic challenge (e.g., syngeneic
tumor cells or bacterial, viral, or parasitic
agents) later in life (6-8). Together, these
reports suggest that in utero immunotoxi-
cant exposure may alter development of
immunity, and that such exposure during
development may lead to severe and
sustained postnatal immunosuppression.
Currently available reports suggest that
immune changes, such as those described
above, may occur in rodents after exposure
to a variety of diverse environmental
immunotoxicants, including numerous pes-
ticides, fungicides, heavy metals, carcino-
genic PAHs, and polycyclic halogenated
hydrocarbons (PHAH) (the most notable
and studied member of the latter group
being 2,3,7,8-tetrachlorodibenzo-p-dioxin
[TCDD]) (1,9,10). The sensitivity of the
developing immune system to estrogenic
compounds (7,8,11) has raised additional
questions regarding potential developmen-
tal immunotoxicity after gestational expo-
sure to environmental pollutants that are
referred to as endocrine disrupters [e.g.,
1,1,1-trichloro-2,2-bis(p-chlorophenyl)-
ethane (DDT), kepone]. Mycotoxins, such
as the trichothecene fungal metabolite
T2 toxin, may also warrant concern as
developmental immunotoxicants (12,13).
Use of Routine Immune Tests
to Detect Developmental
Immunotoxicants
Although perinatal exposure to immunotox-
ic agents has been found to alter immune
development in experimental studies, little
information is available regarding appropri-
ate tests that may adequately detect devel-
opmental immunotoxic agents. Recently,
data collected and analyzed from rodent
studies in adult mice employing over 50
immunotoxicants indicated that the perfor-
mance ofonly two or three immune tests is
usually sufficient (>90% concordance) for
immunotoxic compound identification
(Figure 1). Certain of these immune tests
(e.g., thymus/body weight ratio; 68% pre-
dictability) applywell to the developmental
model, while other tests (e.g., plaque-form-
ing cell assay) are not readily adaptable.
One ofthe tests with a high individual pre-
dictive value for immunotoxicity, surface
marker expression (83% predictability),
applies readily to developmental models.
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Figure 1. Individual and pairwise concordance to establish predictability using the immune panel. Values are pre-
sented as percentage concordance (calculated as the sum of specificity and sensitivity). Abbreviations: NK, natural
killer; MLR, mixed lymphocyte response; CTL, cytotoxic T lymphocyte; BW, body weight; LPS, lipopolysaccharide.
Individual concordance values are shown in boldface on the diagonal of the matrix and combinations, using two
tests, on the off-diagonal element. Values in parentheses are the number of chemicals tested for the assay. p
Values are given for individual concordance only. Data from Luster et al. (14).
However, before these assays are adapted as
part of routine developmental toxicity
studies, it will be necessary to determine
their sensitivity, reproducibility, and
predictive value.
Indicators of Developmental
Immunotoxicity
Recent experiments in which pregnant
laboratory rodents were exposed to a vari-
ety of immunotoxic compounds indicate
that fetal thymus and liver immune cells
are quantitatively and qualitatively altered
by immunotoxicant exposure and, thus,
may serve as sensitive markers of develop-
mental immunotoxicant exposure. For
instance, pregnant mice treated via gavage
from gestational days (gd) 13-17 with 50
or 100 mg/kg B[a]P had markedly reduced
numbers offetal thymocyte cells on gd 18
(15). The investigators in these studies did
not conduct additional experiments with
decreased dose levels of B[a]P to identify
an exposure that would not affect thymic
cellularity nor was the time of dosing var-
ied to evaluate the effects of chemical
administration at other (earlier) periods of
gestation. However, considering the ability
of PAH to readily cross human skin, and
in light of the recent demonstration that
total PAH in skin oil ofroad paving crews
may reach 1400 ng/cm2 (16), these data
raise questions about possible effects of
PAH on fetal immune development in
humans exposed occupationally. Dosing of
pregnant mice with an additional PAH,
7,12-dimethylbenz[a]anthracene (DMBA),
was also found to produce hypocellularity
of the fetal thymus during late gestation
(17). Additional studies showed that total
numbers of fetal thymic cells decrease in
mice after maternal dosing with a broad
range of chemically diverse immunotoxic
compounds, under a variety of dosing
regimens (Table 1).
Certain of these compounds (e.g.,
TCDD and diethylstilbesterol [DES]) pro-
duce fetal thymic atrophy after exposure to
extremely low levels, supporting the consid-
eration ofthis parameter as a biomarker of
environmental immunotoxicant exposure.
The primary hematopoietic compart-
ment ofthe fetus is the liver and functions
similar to adult bone marrow (23).
Qualitative and quantitative effects of
developmental exposure to immunotoxic
compounds on fetal liver cellularity have
also been examined. Fetal liver hemato-
poiesis is first detectable in mice by day 10
of gestation and in humans by the sixth
week of gestation (24,25). This compart-
ment, containing multiple lineages of
rapidly proliferating immune cell types,
soon thereafter replaces the yolk sac as the
primary center of fetal hematopoiesis, a
change that persists for the remainder of
gestation (23). Treatment ofadult animals
with a number of immunotoxic agents,
including T2 toxin (26), ethylene glycol
monomethyl ether (EGME) (27), and
B[a]P (28) significantly reduces cell counts
in the bone marrow. However, recent
results indicate that exposure of pregnant
animals to immunotoxicants that produce
fetal thymic atrophy may or may not result
in decreased total hematopoietic cell num-
ber in the fetal liver. For instance, dosing
of mice with EGME from gd 10-17
reduced cellularity of the gd 18 fetal thy-
mus without altering total cell counts in
the fetal liver (22). Similarly, mice exposed
to DES from gd 10-16 displayed severe
reduction of fetal thymic cell counts with-
out altering fetal liver cellularity (11).
Treatment of mice with 1.5 mg/kg T2
mycotoxin from gd 14-17 also reduced
thymic cellularity, to 32.5% ofthe control
level, without altering fetal liver cellularity
(12). In contrast, B[a]P reduced both fetal
Table 1. Immunotoxicants producing fetal thymic atrophy.
Immunotoxicant Exposure regimen References
2,3,7,8-Tetrachlorodibenzo-p-dioxin 1.5-3.0 pg/kg/day gd 6-14 (18,19)
2,3,7,8-Tetrachlorodibenzo-p-dioxin 10 pg/kg gd 14 (20)
3,3',4,4'-Tetrachlorobiphenyl 6-16 mg/kg gd 12 (21)
Diethylstilbesterol 3.0-8.0 pg/kg/day gd 10-16 (11)
Ethylene glycol monomethyl ether 100-200 mg/kg/day gd 10-17 (22)
Benzo[a]pyrene 50-150 mg/kg/day gd 14-17 (15)
7,12-Dimethylbenz[a]anthracene 10-25 mg/kg/day gd 14-17 (17)
T2 mycotoxin 1.2-1.5 mg/kg/day gd 14-17 (12,13)
gd, gestational day(s).
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thymic and fetal liver cellularity in mice
(15). However, the reduction in fetal thy-
mus cellularity by B[a]P appears to be
greater than that seen in fetal liver at corre-
sponding doses. These studies suggest that
fetal liver cellularity may not be altered fol-
lowing exposure to moderate, or, in some
cases, relatively high levels of known
immunotoxicants. Thus fetal liver cellulari-
ty may not be the most sensitive indicator
ofdevelopmental immunotoxicity.
Chemical Effects
Although the total number of fetal liver
hematopoietic cells appears insensitive,
qualitative changes within this compart-
ment may occur and provide sensitive indi-
cators ofexposure. For example, after a sin-
gle maternal dose of 10 mg/kg TCDD in
mice on gd 14, fetal liver lymphoid cells
have only 40% of the control capacity to
biosynthesize the DNA polymerase, termi-
nal deoxynucleotidyltransferase (TdT) (20).
TdT+ cells in fetal liver indude prothymo-
cytes, the immediate precursors of thymo-
cytes (29), and values for TdT biosynthesis
correlate with total numbers of TdT+ cells
observed by immunofluorescence (30).
Thus, the reduced capacity of fetal liver
from TCDD-exposed animals to synthesize
TdT suggests an altered stem cell popula-
tion in treated mice that may be responsible
for thymic atrophy. This hypothesis was
supported by experiments in which irradiat-
ed hosts reconstituted with stem cells from
vehicle or TCDD-exposed animals demon-
strated reduced capacity of the chemical-
exposed stem cells to reconstitute the host
thymus (20). It is worth noting that thymic
TCDD levels ranged from 1 to 31 fg of
TCDD/mg tissue in these experiments,
emphasizing the extreme sensitivity that
both fetal thymic cell counts and depressed
fetal liver TdT biosynthesis may have as
markers of exposure to this widespread
environmental contaminant.
DES shares with TCDD the ability to
produce fetal thymic atrophy at dose levels
in the low micrograms per kilogram range,
without altering cellularity of the fetal
liver. Analysis of cell-surface antigen
expression on gd 18 fetal liver hematopoi-
etic cells ofmice exposed to DES from gd
10-16 demonstrated no changes relative
to vehicle-treated animals in the percent-
age of CD44+ (hematopoietic precursors),
CD45R+ (B-lineage lymphocytes), or
Mac-I+ (granulocytic) cells (11). How-
ever, TdT+ cells were reduced, again sug-
gesting possible prothymocyte targeting.
Experiments in which irradiated hosts
were reconstituted with stem cells from
vehicle or DES-exposed animals demon-
strated reduced capacity of the chemical-
exposed stem cells to reconstitute the host
thymus, indicating that thymic atrophy
after exposure to DES may result, at least
in part, from a fetal liver lesion at the level
of the T-cell progenitor. These data again
suggest the use of fetal liver TdT as a
sensitive marker of exposure to DES, and
possibly other endocrine disrupters.
EGME and T2 mycotoxin represent
additional immunotoxic agents that alter
the expression of immune cell antigens in
fetal liver in the presence of unaltered
total organ cellularity. Additional reports
indicate developmental exposure to B[a]P
and DMBA alters fetal liver antigen
expression, in the presence of reduced
fetal liver cellularity. A summary of fetal
liver antigens for which data have been
collected after gestational immunotoxi-
cant exposure is presented in Table 2. Of
note, many of these studies have demon-
strated relatively selective targeting of
prolymphoid cell subpopulations in fetal
liver by the immunotoxic agents. In
particular, studies employing CD44
demonstrated reduction ofCD44dim (pro-
lymphocytic) cells (12,31,32), consistent
with chemical targeting of prolymphoid
cells in fetal liver. When examined,
expression of CD45R, an antigen
expressed on pre/pro-B lymphocytes and
some prothymocytes (31), was also
reduced in the fetal liver. Taken together,
these reports indicate that prolymphoid
cells in fetal liver represent sensitive
targets of immunotoxic chemicals, and
therefore mayserve as sensitive biomarkers.
In addition to altering surface antigen
expression in fetal liver, developmental
immunotoxicants have been found to alter
surface antigens expressed on fetal thymo-
cytes. Ontogenic development in the fetal
thymus originates when prothymocytes of
fetal liver origin seed the murine thymic
rudiment on gd 10-11. Thymocytes then
differentiate and mature in a process that
can be followed by CD4 and CD8 cell-
surface antigen expression. Initially, thy-
mocytes are double negative (DN) with
respect to the CD4 and CD8 antigens.
Subsequently, they develop sequentially
through immature CD8+ single positive
(SP) and CD4+8+ double positive (DP)
stages in the thymic cortex, to mature
CD4+ SP or CD8+ SP thymocytes in the
thymic medulla by gd 18-19 (33,34).
Changes in the normal pattern of thymo-
cyte development have been observed after
gestational exposure to a variety of envi-
ronmental immunotoxicants. For exam-
ple, mice exposed prenatally to TCDD
display altered CD4 and CD8 antigen
expression at gd 18 (Table 3). In particu-
lar, TCDD-treated mice displayed
reduced percentages of DP thymocytes
(the most mature major population pre-
sent at gd 18) and increased percentages
of DN and CD8+ SP thymocytes (the
most immature phenotypes present at gd
18), consistent with inhibition of thymo-
cyte maturation. Interestingly, a similar
Table 2. Fetal liver markers altered bygestational immunotoxicant exposure.
Markers evaluated
Immunotoxicant TdT CD44 CD45 CD45R Mac-1 References
TCDD + ND ND ND ND (20)
DES + ND ND ND ND (11)
EGME ND + + + - (22)
B[aIP + + ND + ND (15)
DMBA ND + ND + + (17)
T2toxin ND + ND + - (12,13)
Abbreviations: ND, not determined; +, the compound altered expression of the particular marker; -, the compound
did not alterexpression ofthe marker.
Table3. Effect ofTCDD on fetal thymocyte CD4 and CD8 antigen expression.
CD marker expression (% positive)
Treatment CD4+8 CD4+8+ CD4-8- CD4-8+
Vehicle 1.8±0.2 69.1±1.2 21.1±0.7 8.1±0.7
1.5 pg/kg 1.5±0.1 52.6±2.5* 30.3±1.8' 15.5±0.9
3.0 pg/kg 2.0±0.2 43.2±4.5' 37.3±3.7* 17.5±0.9
CD4 and CD8 surface antigen expression determined in gestational day 18 fetal mice after maternal exposure to
1.5 or 3.0 mg/kg/day TCDD from gestational days 6-14. Values represent mean ± SEM of five mice per treatment
group. p<0.05 vs vehicle controls. Adapted from Holladay et al. (18).
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Table 4. Effect of gestational exposure on the percentage of CD4+8+(DP) and CD4-8- (DN) phenotypes from gesta-
tional day 18 fetal thymocytes.
% within phenotype
Control Treated
Agent Exposure regimen DP DN DP DN References
TCDD 3.0 pg/kg/day gd 6-14 69.1 21.1 43.2 37.3' (18)
DES 3.0-8.0 pg/kg/day gd 10-16 71.4 22.0 63.6 29.2* (11)
EGME 200 mg/kg/day gd 10-17 82.1 12.0 72.3 19.9' (22)
B[a]P 50-150 mg/kg/day gd 14-17 78.0 18.1 33.4 62.0* (15)
T2 toxin 1.2-1.5 mg/kg/day gd 14-17 71.6 23.6 55.0 40.2* (12)
Abbreviations: TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; DES, diethylstilbesterol; EGME, ethylene glycol
monomethyl ether; B[a]P, benzo[alpyrene; gd, gestational day(s); *indicates numbers were reported as significantly
different from control, p<0.05.
pattern ofaltered thymocyte differentiation,
including reduced percentages ofDP thymo-
cytes and increased percentages of DN thy-
mocytes, has been reported after gestational
exposure to a diverse variety ofimmunotoxic
compounds (summarized inTable4).
Although specific mechanisms responsi-
ble for such altered thymocyte differentia-
tion after exposure to these compounds
have not been elucidated, apoptosis of DP
cells may be involved (10-12,15,18,22).
In summary, depression offetal thymic
cell counts appears to be a common event
after gestational exposure to immunotoxic
agents that produce this response in adult
animals. The relation of fetal thymic
atrophy to postnatal immunosuppression is
not known. In contrast, total hematopoietic
cell counts in the fetal liver may represent a
poor indicator of immunotoxicant expo-
sure. Regardless of whether an immuno-
toxic compound altered fetal liver cellulari-
ty, however, immune cell markers in fetal
liver were found to be altered following
immunotoxicant treatment in all cases
where such data were available. These
reports indicate that fetal liver cells may
represent highly sensitive targets of
immunotoxic chemicals, and, as such, may
represent a sensitive indicator of exposure.
Similar to fetal liver, altered fetal thymocyte
marker expression appears to be a sensitive
indicator of gestational immunotoxicant
exposure. The findings in fetal liver and
thymus agree well with the recent observa-
tion in adult rodents that altered immune
cell marker expression is a good indicator
for immunotoxic agents (14).
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